Tumor Acidic Microenvironment Targeted Drug Delivery Based on Phlip-Modified Mesoporous Organosilica Nanoparticles
Yunlei Zhang,Meng Dang,Ying Tian,Yefei Zhu,Wenfei Liu,Wei Tian,Yunyan Su,Qianqian Ni,Chaoli Xu,Nan Lu,Jun Tao,Yanjun Li,Shuang Zhao,Ying Zhao,Zhenlu Yang,Li Sun,Zhaogang Teng,Guangming Lu
DOI: https://doi.org/10.1021/acsami.7b10840
IF: 9.5
2017-01-01
ACS Applied Materials & Interfaces
Abstract:Enhancing the tumor-targeting delivery of chemotherapeutic drugs is important yet challenging for improving therapeutic efficacy and reducing the side effects. Here, we first construct a drug delivery system for targeting tumor acidic microenvironment by modification of pH (low) insertion peptide (pHLIP) on mesoporous organosilica nanoparticles (MONs). The MONs has thioether-bridged framework, uniform diameter (60 nm), good biocompatibility, and high doxorubicin (DOX) loading capacity (334 mg/g). The DOX loaded in the pHLIP modified MONs can be released responsive to glutathione and low pH circumstance, ensuring the chemotherapeutic drug exerts higher cytotoxic effects to cancer cells than normal cells because of high intracellular GSH of tumor cells and low pH of tumor microenvironment. Moreover, the engineered MONs exhibit higher cellular uptake in pH 6.5 medium by MDA-MB-231 and MCF-7 cells than the particles decorated with polyethylene glycol (PEG). Importantly, the pHLIP-mosaic MONs with DOX displays better cytotoxic effects against the breast cancer cells in pH 6.5 medium than pH 7.4 medium. The in vivo experiments demonstrate that the pHLIP modified MONs are accumulated in the orthotopic breast cancer via targeting to acidic tumor microenvironment while no serious pathogenic effects was observed. After loading DOX, the pHLIP-modified MONs display better therapeutic effects than the control groups on the growth of MCF-7 breast cancers, showing promise for enhancing chemotherapy.